Findings

What do systematic reviews say?

Ignored "OS": search terms need at least 3 characters.

8 questions · 8 findings · 2 reviews · Haematology

Sort:Best matchNewest Highest certainty Download CSV

No studies found 1 · 12.5%GRADE not reported 0 · 0%Very low 6 · 75%Low 0 · 0%Moderate 1 · 12.5%High 0 · 0%

Intervention not reported

Mortality sensitivity analysis (calculated instead of overall survival) ‐ without UK NCRI Rapid trial and MSKCC trial #90‐44due to high risk of other bias

The intervention probably leads to lower mortality sensitivity analysis (calculated instead of overall… (moderate certainty).

1 finding from 1 review

Chemotherapy alone versus chemotherapy plus radiotherapy for adults with early stage Hodgkin lymphoma 2017 · Cochrane Headline outcomes only
HR 0.31 [0.19, 0.52]
3 studies · 816 participants
Moderate

Nivolumab vs no other intervention

OS · adults with Hodgkin's lymphoma

1 finding from 1 review

Nivolumab for adults with Hodgkin's lymphoma (a rapid review using the software RobotReviewer) 2018 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 260 participants
Very low

Nivolumab vs no other intervention

QoL · adults with Hodgkin's lymphoma

1 finding from 1 review

Nivolumab for adults with Hodgkin's lymphoma (a rapid review using the software RobotReviewer) 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 80 participants
Very low

Nivolumab vs no other intervention

PFS · adults with Hodgkin's lymphoma

1 finding from 1 review

Nivolumab for adults with Hodgkin's lymphoma (a rapid review using the software RobotReviewer) 2018 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 283 participants
Very low

Nivolumab vs no other intervention

Response rate · adults with Hodgkin's lymphoma

1 finding from 1 review

Nivolumab for adults with Hodgkin's lymphoma (a rapid review using the software RobotReviewer) 2018 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 283 participants
Very low

Nivolumab vs no other intervention

Treatment‐related mortality · adults with Hodgkin's lymphoma

The review found no eligible studies for this question.

1 finding from 1 review

Nivolumab for adults with Hodgkin's lymphoma (a rapid review using the software RobotReviewer) 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Nivolumab vs no other intervention

Grades 3 and 4 adverse events · adults with Hodgkin's lymphoma

1 finding from 1 review

Nivolumab for adults with Hodgkin's lymphoma (a rapid review using the software RobotReviewer) 2018 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 283 participants
Very low

Nivolumab vs no other intervention

SAEs · adults with Hodgkin's lymphoma

1 finding from 1 review

Nivolumab for adults with Hodgkin's lymphoma (a rapid review using the software RobotReviewer) 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 243 participants
Very low